Olema Pharmaceuticals (OLMA) Total Liabilities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Total Liabilities data on file, last reported at $50.2 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 91.57% year-over-year to $50.2 million in Q1 2026; TTM through Mar 2026 was $50.2 million, a 91.57% increase from a year earlier, with the FY2025 full-year figure at $54.9 million, up 30.6% from the prior year.
• Total Liabilities for Q1 2026 stood at $50.2 million, down from $54.9 million in the prior quarter.
• Over the last five years, Total Liabilities for OLMA reached as high as $54.9 million in Q4 2025 and fell as low as $12.3 million in Q1 2022.
• Historically, Total Liabilities has averaged $28.1 million across 5 years, with a median of $26.2 million in 2025.
• Across the five-year window, Total Liabilities surged 133.62% in 2022 and fell 4.34% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $18.1 million in 2022, then increased by 27.36% to $23.0 million in 2023, then surged by 82.28% to $42.0 million in 2024, then surged by 30.6% to $54.9 million in 2025, then fell by 8.57% to $50.2 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $50.2 million in Q1 2026, $54.9 million in Q4 2025, and $45.0 million in Q3 2025.